"None, it won't happen"
What is your premise?
ARDS has just as much chance as CHF & CLBP.
In my opinion, it has a better chance of success due to the severity of inflammation and the fact the majority of the cells are trapped in the lungs after infusion. Naturally targeted you could say.
I just don't get people thinking we have a low chance with ARDS. Quite the contrary.
If your reason is that the market is so large and competition so fierce with so many phase III's in the works. That is frankly hogwash.
If it works it will be approved and all signs to date point to it working and working well across the many MSC ARDS sample size trials. It's not just MSB but multiple companies around the world who have 70%+ survival also.
Comparing them however, MSB just has the leg up with a NIH funded, fast track, phase III, gold standard RCT trial. Not to mention the patent.
Just don't understand your position. MSB ARDS has a high chance of success.
MSB Trading 2020 - a new dawn, page-6261
-
- There are more pages in this discussion • 6,810 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |